Acadia Pharmaceuticals | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Acadia Pharmaceuticals USD 126.37M 3.71M 2025-03
ALKERMES USD 171.7M 24.71M 2025-03
Alnylam Pharmaceuticals USD 239.95M 55.39M 2025-03
Biogen USD 572.5M 104.8M 2025-03
BioMarin Pharmaceutical USD 206.12M 50.65M 2025-03
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Corcept Therapeutics USD 90.66M 7.29M 2025-03
Cytokinetics USD 57.37M 4.97M 2025-03
Eisai JPY 106.51B 1.99B 2025-03
Eli Lilly USD 2.36B 62.3M 2025-03
Incyte USD 325.69M 1.02M 2025-03
J&J USD 5.11B 1.34B 2025-03
Moderna USD 212M 139M 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Pfizer USD 3.01B 1.27B 2025-03
Prothena USD 16.85M 88K 2024-12
PTC Therapeutics USD 161.92M 77.24M 2025-03
Sarepta Therapeutics USD 133.63M 30.24M 2025-03
Ultragenyx Pharmaceutical USD 87.8M 5.3M 2025-03
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Acadia Pharmaceuticals Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.